BioSpace News Archive

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced that the company will present a poster at the upcoming American Association for Cancer Research 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

IO Biotech announced updated efficacy data and subgroup analyses from the MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 as investigational agents in metastatic melanoma in an e-poster presentation at the American Association of Cancer Research conference, being held April 8-13, 2022 in New Orleans, Louisiana.

Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for Cancer Research Annual Meeting in New Orleans on April 8-13, 2022.

Shattuck Labs, Inc. announced preclinical data at the 2022 American Association for Cancer Research Annual Meeting.

Forward Pharma A/S, reported consolidated financial results for the year ended December 31, 2021.

NANOBIOTIX announced the filing of its universal registration document for the financial year ended December 31, 2021 with the French financial market authority, as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2021 with the U.S. Securities and Exchange Commission.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 37,538 restricted stock units of Atara’s common stock to five newly hired employees.

Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted non-statutory stock options to two new employees on April 6, 2022.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand, Ph.D., its new Chief Operations Officer.